The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

Recently, a randomized controlled clinical trial of the innovative medical device "3D printing fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" independently developed by Beijing Amat Medical Devices Co., Ltd. was conducted in Beijing affiliated to Capital Medical University. Anzhen Hospital successfully completed the enrollment of the first three subjects (including two in the experimental group and one in the control group). All three subjects were in good postoperative condition and have been discharged from the hospital.

2021

07-13

Beijing Amet officially obtained the ISO 13485 quality management system certification issued by BSI

Recently, Beijing Amet Medical Devices Co., Ltd. officially obtained the ISO 13485:2016 medical device quality management system certification issued by BSI British Standards Institute. The scope of this certification includes the design and development of Amet's products of a fully degradable peripheral vascular drug-eluting stent system and a high-pressure balloon dilation catheter.

2021

05-14

Beijing Amet Medical Equipment Co., Ltd. was selected as one of the top 200 in the 2020 Venture50 Billboard

Recently, the preliminary list of the 15th China's Top 50 Most Valuable Investment Enterprises (Venture50) was officially announced, and Beijing Amat was selected as the top 200 in the 2020 Venture50 Billboard.

2021

01-15

The project that Beijing Amet participated in the application was approved by the "National Natural Science Foundation of China"

Recently, the National Natural Science and Technology Fund project led by Beijing University of Aeronautics and Astronautics, Beijing Natong Medical and Beijing Amet Medical Equipment Co., Ltd. participated in the joint application was approved. The project will focus on the research on key technical and scientific issues in the optimal design and safety evaluation of bone and cardiovascular absorbable implantable interventional devices.

2021

01-14

Beijing Amet was approved to set up a postdoctoral workstation

Recently, the Ministry of Human Resources and Social Security of the People's Republic of China and the National Postdoctoral Management Committee issued a document that approved the establishment of postdoctoral research stations by 497 units including the Advanced Technology Research Institute of the University of Science and Technology of China. in.

2020

11-28

Our company and the Department of Materials of Fudan University will jointly develop new degradable materials

On November 16, 2020, our company and the Department of Materials of Fudan University signed an agreement to jointly develop a new generation of degradable materials.

2020

11-16

[CCI Innovation Weekly News] Abbott Restarts Clinical Trial of Bioresorbable Stent, Novel Esprit Below-Knee Stent

September 3, 2020 - Abbott announced today the LIFE-BTK clinical trial to evaluate the safety and efficacy of the company's new Esprit BTK everolimus-eluting absorbable stent system. This is the first investigational device waiver (IDE) trial in the United States designed to evaluate a fully bioabsorbable stent for the treatment of patients with advanced peripheral arterial disease (PAD) with below-the-knee arterial occlusion or critical limb ischemia (CLI). New York-Presbyterian/Columbia University Irving Medical Center vascular surgeon Danielle Bajakian, MD, enrolled the first patient.

2020

09-10

Our company's patent application for vascular stent structure design has been authorized by the State Intellectual Property Office for invention patents

Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

2020

07-07

Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials

Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

2020

06-15

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

2016

08-12

< 1234 > proceed page

Company Information

Beijing Advanced Medical Technologies, Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel：010-6297-7955           E-Mail：amt@ametcorp.com

Picture Name

WeChat Contact

@Copyright 2022 Beijing Advanced Medical Technologies, Inc. All rights reserved

京ICP备11028039号   Powered by: www.300.cn   SEO